广告品牌策划模板

Clinical trials are a crucial step in testing the safety and efficacy of new drugs, and clinical blinding is a core step in ensuring the objectivity and reliability of test results. At the beginnin...

On October 14, 2025, the registration application for the recombinant herpes zoster vaccine (CHO cells) independently developed by Shanghai Maikang Biotechnology Co., Ltd. (referred to as "Shanghai...

Recently, the cooperative research paper "Enhanced Antitumor Immunity of a Globo H-Based Vaccine Enabled by the Combination Adjustments of 3D-MPL and QS-21", developed by Chengdu Maikekang Biotechn...

Birds chirping and fireworks enveloping, people walking in the grass; The pond suddenly disperses, and the flowers meet again. It is April in Jiangnan, with a warm spring breeze and all things thrivin

At 16:16 in the afternoon, accompanied by a cheerful rhythm of children's singing "Happy Birthday to You", the staff entered the venue on time and gathered together. 14 birthday stars were arranged in

In the name of basketball, go on a youthful journey! On June 1st at 18:00, the 2023 Simbay Park Life Science Basketball League, sponsored by Xingbei Group and co organized by the Shanghai Pilot Free T

The 9th Vaccine China Leaders Annual Meeting held by Shiyan Life Sciences in 2024 was held as scheduled on October 30, 2024 at 8:30 am at the Grand Hyatt Shanghai Pudong New Area, No. 1199 Yingchun Ro

On July 13th, the Phase III clinical trial of the recombinant herpes zoster vaccine (CHO cells) of Chengdu MAXVAX Biotechnology Co., Ltd. (referred to as "MAXVAX Biotechnology") completed with the ...

The key to international cooperation in technological innovation is to establish communication and connections, and the best way to achieve this is through people with good relationships international

On June 28, 2024, Chengdu MAXVAX Biotechnology Co., Ltd. announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration has approved its application for clinica...

In June 2024, Chengdu MAXVAX Biotechnology Co., Ltd. (hereinafter referred to as "MAXVAX Biotechnology") announced that it had received over 300 million yuan in Series C financing. This round of...

On the morning of May 19th, representatives from Chongqing Modern Industry Research Institute conducted research on the Shanghai Innovation Vaccine Transfer Platform of Maikekang Biotechnology. Mr. Zo

On May 6th, the kickoff meeting for the Phase II clinical trial of the recombinant herpes zoster vaccine (CHO cells) by Chengdu Maikekang Biotechnology Co., Ltd. (referred to as "Maikekang Biotechnolo

On the morning of April 20th, Yuan Quan, Deputy Secretary of the Fengxian District Committee and District Mayor of Shanghai, led a team to investigate the "Innovative Vaccine Transfer Platform" projec

On April 12, 2024, Chengdu Maxvax Biotechnology Co., Ltd. (referred to as "Maxvax Biotechnology") announced that its independently developed and jointly applied by its wholly-owned subsidiary fo

On December 29, 2023, the BRD Shanghai Biomedical Innovation and Development Conference arrived as scheduled, with a gathering of experts on site. The preparatory party for this conference, Pharmaceut